江苏四环生物股份有限公司 2018 年第一季度报告正文 证券代码：000518 证券简称：四环生物 公告编号：临-2018-17 号 江苏四环生物股份有限公司 2018 年第一季度报告正文 1 江苏四环生物股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐海珍声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | 营业收入（元） | 86,036,603.08 | 107,067,159.81 | | -19.64% | | 归属于上市公 ...

Financial Performance - The company's operating revenue for 2017 was CNY 346,054,646.61, representing a 5.73% increase compared to CNY 327,313,301.33 in 2016[18]. - The net profit attributable to shareholders for 2017 was CNY 7,288,394.73, a significant increase of 62.94% from CNY 4,472,925.91 in 2016[18]. - The basic earnings per share for 2017 was CNY 0.0071, up 65.12% from CNY 0.0043 in 2016[18]. - Total revenue for 2017 reached ¥346,054,646.61, representing a year-on-year increase of 5.73% compared to ¥327,313,301.33 in 2016[37]. - The company reported a significant increase in inventory levels, with Interleukin inventory rising by 188.65% to 625,310 units[41]. - The company reported a significant reduction in financial expenses by 85.98% to ¥1,867,260.57, as last year's figures included interest payments related to litigation[51]. - The company reported a significant reduction in accounts payable from CNY 313,105,818.90 to 19,103,191.98, a decrease of about 93.9%[171]. - The company reported a decrease in cash and cash equivalents of ¥24,221,531.36 for the period[186]. - The total comprehensive income for the period was CNY 10,650,335.19, compared to CNY 5,608,661.99 in the previous period, indicating a growth of 89.56%[179]. Cash Flow and Investments - The net cash flow from operating activities was negative CNY 10,785,813.91, a decline of 193.14% compared to a positive CNY 11,579,773.72 in 2016[18]. - Operating cash inflow totaled ¥362,422,720.30, a 17.60% increase from the previous year, while operating cash outflow rose by 52.97% to ¥453,688,363.43[53]. - Investment cash inflow increased by 52.30% to ¥52,021,223.31, primarily due to cash inflow from the disposal of equity in Jiangsu Sihuan Biopharmaceutical Co., Ltd.[54]. - Cash inflow from investment activities was ¥52,021,223.31, compared to ¥34,157,482.54 in the previous period, indicating a growth of approximately 52.2%[186]. - The net cash flow from investment activities was ¥28,875,496.70, significantly higher than ¥9,344,549.68 in the previous period[186]. Assets and Liabilities - Total assets at the end of 2017 were CNY 931,628,406.78, down 8.43% from CNY 1,017,357,931.64 at the end of 2016[18]. - Total liabilities decreased to CNY 256,083,448.72 from CNY 406,262,908.77, a reduction of approximately 37%[172]. - The company's cash and cash equivalents decreased to CNY 40,728,343.14 from CNY 64,949,874.50, a decline of about 37.4%[169]. - The total assets decreased to CNY 931,628,406.78 from CNY 1,017,357,931.64, reflecting a decline of about 8.4%[172]. - The company's equity increased to CNY 675,544,958.06 from CNY 611,095,022.87, an increase of approximately 10.5%[172]. Business Operations and Strategy - The company plans not to distribute cash dividends or issue bonus shares for the year[6]. - The company is transitioning towards the ecological agriculture and forestry industry, with the establishment of Jiangsu Chenwei Ecological Park Technology Co., Ltd. in 2015[27]. - The company aims to consolidate its existing market in the pharmaceutical industry and develop new products while expanding into new markets[69]. - The company is actively expanding its landscaping engineering business, accumulating project resources[34]. - The company aims to achieve profitability for Jiangsu Chenwei Ecological Park in the 2018 fiscal year through improved project management[69]. Market and Industry Outlook - The pharmaceutical industry in China is expected to maintain an average annual growth rate of over 10% during the 13th Five-Year Plan period[28]. - The pharmaceutical industry in China is expected to maintain a growth rate higher than 10% annually during the 13th Five-Year Plan period, driven by increasing healthcare awareness and an aging population[68]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2020[121]. Governance and Compliance - The company has established a governance structure to protect minority shareholders' rights and ensure compliance with relevant laws and regulations[98]. - The company has maintained a focus on improving information disclosure management to ensure all shareholders receive equal access to information[98]. - The company has established an independent financial department with its own accounting system and tax obligations, ensuring financial decision-making autonomy[141]. - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with investors[138]. Employee and Management - The total number of employees in the company is 280, with 123 in production, 25 in sales, 67 in technical roles, 14 in finance, and 51 in administration[132]. - The company has implemented a performance evaluation system to objectively assess employee capabilities and work performance, effectively enhancing employee motivation[100]. - The company has established a comprehensive training program to enhance employee skills and management capabilities[100]. - The total remuneration for directors and senior management during the reporting period amounted to 1,147,400 CNY, with the highest being 252,700 CNY for the chairman and general manager[130]. Risks and Challenges - The company faces risks from government price controls on pharmaceuticals, which may negatively impact its performance[68]. - The company reported a decrease in operating income and net profit due to the judicial auction of Jiangsu Sihuan Biological Co., Ltd.[65].

公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐海珍声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2017 年第三季度报告正文 证券代码：000518 证券简称：四环生物 公告编号：临-2017-49 号 江苏四环生物股份有限公司 2017 年第三季度报告正文 1 江苏四环生物股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 江苏四环生物股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 945,937,438.48 | | 1,017,357,931.64 | -7.02% | | 归属于 ...

Financial Performance - The company's operating revenue for the first half of 2017 was CNY 197,309,155.11, representing a 49.46% increase compared to CNY 132,019,042.17 in the same period last year[18]. - The net profit attributable to shareholders was CNY 19,092,935.66, a significant turnaround from a loss of CNY 4,914,240.13, marking an increase of 488.52%[18]. - The basic earnings per share rose to CNY 0.0185 from a loss of CNY 0.0048, reflecting an increase of 485.42%[18]. - The company achieved total revenue of 197.31 million yuan, a year-on-year increase of 49.46%[32]. - Net profit attributable to shareholders reached 19.09 million yuan, up 488.52% compared to the same period last year[32]. - The company reported a significant increase in sales expenses by 124.79% to 74.43 million yuan, primarily due to increased promotional activities[34]. - The gross margin for pharmaceutical revenue was 72.57%, with a year-on-year increase of 9.70%[37]. - The company reported a net loss of ¥463,421,165.03, slightly improved from a loss of ¥482,514,100.69 in the previous period[101]. - The total operating costs increased to CNY 201.08 million from CNY 134.59 million, with the operating cost rising to CNY 67.54 million from CNY 49.61 million, indicating a 36.1% increase[108]. - The company reported an investment income of CNY 22.43 million, compared to no investment income in the same period last year[108]. Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -CNY 294,637,435.45, a decline of 1,061.69% compared to CNY 30,637,387.74 in the previous year[18]. - The company’s cash flow from investment activities showed a net increase of 256.67 million yuan, a 3,996.85% increase, mainly from the disposal of equity stakes[35]. - The company reported a cash balance of 18,344,678.58 CNY at the end of the period, down from 64,949,874.50 CNY at the beginning[117]. - Cash outflow from operating activities totaled 474,417,747.73 CNY, compared to 137,215,179.20 CNY in the previous period, indicating increased operational expenses[116]. - The total cash inflow from operating activities was 30,784,219.84 CNY, significantly higher than 7,364,914.63 CNY in the previous period[118]. - The total cash and cash equivalents decreased by 46,605,195.92 CNY during the period, compared to a decrease of 1,237,551.04 CNY in the previous period[117]. Assets and Liabilities - Total assets decreased by 9.15% to CNY 924,281,540.89 from CNY 1,017,357,931.64 at the end of the previous year[18]. - The company’s total assets decreased by 1.7 million yuan due to the sale of its biopharmaceutical subsidiary[28]. - Current liabilities decreased to ¥237,816,779.57 from ¥405,270,286.77, a reduction of about 41.3%[100]. - The total liabilities decreased to ¥240,079,019.96 from ¥406,262,908.77, a reduction of about 40.8%[100]. - Long-term equity investments decreased to ¥405,788,527.16 from ¥642,805,144.50, a decline of approximately 37%[104]. Shareholder Information - The company did not plan to distribute cash dividends or issue bonus shares for the year[6]. - The total number of shares outstanding is 1,029,556,222, with 100% being unrestricted shares[80]. - The largest shareholder, Kunshan Chuangye Investment Co., Ltd., holds 8.60% of the shares, totaling 88,593,189 shares[84]. - The second-largest shareholder, Zhongwei Small Enterprise Investment Group Co., Ltd., holds 7.09%, totaling 72,994,542 shares[84]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[85]. Strategic Developments - The company has established Jiangsu Chenwei Ecological Park Technology Co., Ltd. to cultivate new profit growth points and gradually transition to the ecological forestry industry[25]. - In January 2017, the company exchanged its 12% stake in Beijing Sihuan for 100% equity in Guangxi Intercontinental, which primarily engages in the planting, maintenance, and sale of eucalyptus trees[25]. - The company is positioned in a rapidly growing pharmaceutical industry, driven by increasing healthcare demands and population aging in China[25]. - The company sold 100% equity of Jiangsu Sihuan Biopharmaceutical Co., Ltd. and exchanged 12% equity of Beijing Sihuan for 100% equity of Guangxi Intercontinental Forestry Investment Co., Ltd.[28]. Compliance and Governance - The half-year financial report has not been audited[57]. - There are no penalties or rectification measures reported for the company during the period[60]. - The company has ongoing commitments from its actual controller and shareholders, including a lock-up period of 24 months for share trading after obtaining circulation rights[55]. - The company has not engaged in any equity incentive plans or employee stock ownership plans during the reporting period[61]. - There are no major related party transactions or significant contracts reported during the period[62][73]. Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements accurately reflect its financial position and operating results[141]. - The company uses Renminbi as its functional currency for accounting purposes[144]. - The company recognizes investment income from interest or dividends during the holding period of financial assets, with fair value changes accounted for at the end of the reporting period[161]. - The company applies an aging analysis method to assess bad debt provisions for receivables, with specific percentages for different aging categories, such as 5% for receivables within one year and 100% for those over five years[170]. - The company recognizes impairment losses for receivables based on individual assessment or aging analysis, ensuring that significant amounts are adequately provisioned[171].

江苏四环生物股份有限公司 2017 年第一季度报告正文 证券代码：000518 证券简称：四环生物 公告编号：临-2017-23 江苏四环生物股份有限公司 2017 年第一季度报告正文 1 江苏四环生物股份有限公司 2017 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐殷声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目，以及把《公 开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应 说明原因 3 江苏四环生物股份有限公司 2017 年第一季度报告正文 单位：元 | 项目 | 年 ...

Financial Performance - The company's operating revenue for 2016 was CNY 327,313,301.33, representing a 37.62% increase compared to CNY 237,843,810.20 in 2015[18]. - The net profit attributable to shareholders was CNY 4,472,925.91, a significant turnaround from a loss of CNY 74,445,499.52 in the previous year, marking a 106.01% improvement[18]. - The net cash flow from operating activities was CNY 19,763,200.81, recovering from a negative cash flow of CNY -136,113,147.28 in 2015, an increase of 114.52%[18]. - Basic earnings per share were CNY 0.0043, compared to a loss of CNY -0.0723 per share in 2015, reflecting a 105.95% improvement[18]. - The company's total revenue for 2016 was CNY 318,975,230.58, representing a 38.76% increase compared to the previous year[39]. - The net profit for the period was CNY 5,608,661.99, a significant recovery from a net loss of CNY 112,903,436.59 in the previous period[179]. - The profit attributable to the parent company's shareholders was CNY 4,472,925.91, compared to a loss of CNY 74,445,499.52 in the previous year[179]. - The total comprehensive income for the current period was 5,608,600 CNY, with a significant increase of 61.99% compared to the previous period[192]. Assets and Liabilities - Total assets at the end of 2016 reached CNY 1,017,357,931.64, a 21.91% increase from CNY 834,527,725.13 in 2015[18]. - Total liabilities increased to CNY 406,262,908.77 from CNY 225,839,223.80, which is an increase of approximately 80%[172]. - Current assets rose to CNY 675,898,983.60, compared to CNY 442,835,563.71 at the beginning of the period, marking a 52.7% increase[171]. - Inventory significantly increased to CNY 461,600,523.85 from CNY 211,949,173.46, reflecting a growth of 117.5%[171]. - The company's equity attributable to shareholders increased slightly to CNY 611,095,022.87 from CNY 606,622,096.96[173]. Revenue Segmentation - The pharmaceutical segment contributed CNY 315.83 million, accounting for 96.49% of total revenue, while the landscape engineering segment generated CNY 6.01 million, representing 1.83% of total revenue[37]. - The revenue from the interleukin product line increased by 7.19% to CNY 122.86 million, while EPO product revenue decreased by 3.08% to CNY 87.21 million[37]. - Sales volume of Interleukin reached 4,456,070 units, a 49.04% increase from 2015[40]. - The sales volume of EPO was 3,987,353 units, reflecting an 18.21% increase year-on-year[40]. Cash Flow Management - Operating cash inflow increased significantly to CNY 316,356,452.44, up 38.25% year-on-year, primarily due to increased sales from Beijing Sihuan[51]. - Operating cash outflow decreased to CNY 296,593,251.63, down 17.39% year-on-year, reflecting improved cash management[51]. - The total cash and cash equivalents increased by CNY 45,094,324.08, a significant turnaround from a decrease of CNY 7,963,189.25 last year[51]. - Cash flow from financing activities resulted in a net inflow of CNY 24,201,259.80, compared to CNY 31,484,540.31 in the previous period, reflecting a decrease of 22.5%[186]. Strategic Initiatives - The company has established a strategic partnership with China Shipbuilding Industry Corporation to expand its landscape engineering business, enhancing growth opportunities[34]. - The company is focusing on optimizing financial structure and risk management to ensure overall financial safety and control[34]. - The company is actively pursuing industry transformation by integrating biopharmaceuticals with agriculture, establishing a new profit growth point[27]. - The company plans to strengthen its existing market position by promoting its key products and expanding into new markets, particularly in the health industry[67]. Governance and Compliance - The company emphasizes the protection of minority shareholders' rights and has established a comprehensive corporate governance structure[101]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with all shareholders[102]. - The company has not experienced any significant accounting errors or changes in accounting policies during the reporting period[78]. - The company’s financial statements received a non-qualified audit opinion, indicating no major adverse effects on its financial status[76]. Employee and Management Structure - The total number of employees in the company is 413, with 179 in production, 46 in sales, 108 in technical roles, 10 in finance, and 70 in administration[136]. - The company has implemented a training plan to enhance the overall quality and business skills of its personnel[139]. - The remuneration policy aims to provide fair treatment and equal opportunities, linking compensation to job value, employee performance, and team performance[138]. - The company has maintained a consistent management structure with no changes in shareholding among current executives[125]. Legal and Regulatory Matters - The company is currently involved in a lawsuit regarding a seedling purchase and sale contract dispute, with a claimed amount of 289.59 million CNY, which is in the execution phase[81]. - The company has a pending dispute with Taiyuan Tianhai Hengda Co., Ltd. involving an amount of 10.8756 million CNY, which has not yet gone to court[82]. - The company has not faced any penalties or rectification issues during the reporting period[83].

Financial Performance - Operating revenue for the reporting period reached CNY 87,856,894.71, a year-on-year increase of 30.85%[8] - Net profit attributable to shareholders increased by 275.22% to CNY 15,282,016.85 compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 372.33% to CNY 14,863,423.40[8] - Basic earnings per share increased by 274.12% to CNY 0.0148[8] - Operating profit increased by 35.95% to ¥15,853,931.68, with a reduction in losses for Xinjiang Aidi compared to the same period last year[15] Asset and Liability Changes - Total assets increased by 31.78% to CNY 1,099,711,779.53 compared to the end of the previous year[8] - Cash and cash equivalents increased by 136.09% to ¥56,878,999.29 due to proceeds from asset disposals[15] - Accounts receivable decreased by 63.81% to ¥7,263,509.20, reflecting a reduction in receivables by ¥11.5 million[15] - Inventory rose by 120.13% to ¥466,564,635.12, attributed to new purchases of engineering seedlings by a subsidiary[15] - Accounts payable surged by 281.80% to ¥321,726,478.69, driven by new payables for engineering seedlings[15] Cash Flow Analysis - The company reported a net cash flow from operating activities of CNY 23,839,730.31, an increase of 114.52% year-to-date[8] - Net cash flow from operating activities improved significantly to ¥23,839,730.31 from a negative ¥164,141,020.64 in the previous year[15] - Cash flow from investing activities decreased by 94.73% to ¥5,589,417.99, down from ¥106,137,356.49 due to last year's recovery of entrusted loans[15] - Cash flow from financing activities fell by 77.19% to ¥7,308,391.25, as new loans were lower compared to the previous year[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 87,969[11] - The largest shareholder, Kunshan Chuangye Investment Co., Ltd., holds 7.06% of the shares[11] Accounting and Expense Changes - There were no significant changes in the company's accounting policies or restatements of previous financial data[8] - The company reported a significant reduction in sales expenses, which increased by 54.35% to ¥44,371,805.13, reflecting higher operational costs[15] - Cash received from sales of goods and services grew by 44.28% to ¥225,350,873.97, indicating increased sales activity[15] Return on Investment - The weighted average return on net assets was 2.50%, an increase of 3.78% compared to the previous year[8]

Financial Performance - The company achieved a revenue of ¥132,019,042.17, representing a year-on-year increase of 21.45%[21]. - The net profit attributable to shareholders was -¥4,914,240.13, a decline of 219.95% compared to the previous year[21]. - The net profit after deducting non-recurring gains and losses was -¥4,299,279.57, a decrease of 489.50% year-on-year[21]. - The net cash flow from operating activities improved to ¥30,637,387.74, a significant increase of 118.30% compared to the previous year[21]. - Total operating revenue for the first half of 2016 was CNY 132,019,042.17, an increase of 21.5% compared to CNY 108,698,999.38 in the same period of 2015[116]. - The net loss for the first half of 2016 was CNY 5,278,598.46, compared to a net profit of CNY 2,246,052.38 in the same period last year[116]. - The company reported a significant decrease in sales expenses, which dropped to CNY 188.68 from CNY 4,850.00 in the previous period[119]. - The total comprehensive income for the period was -5,278,598.00 CNY, reflecting a loss in the current financial period[131]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,077,532,646.16, up 29.12% from the end of the previous year[21]. - The company's total liabilities reached RMB 474,122,743.29, up from RMB 225,839,223.80, which is an increase of approximately 109.5%[108]. - The company's current assets totaled RMB 670,474,975.66, up from RMB 442,835,563.71, indicating a significant increase of about 51.4%[107]. - Accounts payable rose sharply to RMB 323,532,611.02 from RMB 84,266,599.64, marking an increase of around 284.5%[108]. - The total equity attributable to the parent company was CNY 502,637,646.76, down from CNY 510,562,078.86 at the beginning of the year[113]. Operational Changes and Strategies - The company plans to transition towards "big agriculture" through its subsidiary Jiangsu Chenwei Ecological Park Technology Co., Ltd., and has signed greening subcontract agreements with multiple partners[29]. - The company is in the process of properly disposing of its equity in Xinjiang Aidi, which is currently inactive[29]. - The decline in sales and profits was primarily attributed to Beijing Sihuan's performance[29]. - The company is expanding its operations into the agricultural sector, implementing a diversified development strategy that combines biopharmaceuticals and agriculture[33]. - The company has decided to terminate the Xinjiang Aidi New Energy project due to ongoing challenges including low international oil prices and funding shortages[32]. Shareholder Information - The company has a total of 1,029,556,222 shares outstanding, with 100% being unrestricted shares[89]. - The total number of ordinary shareholders at the end of the reporting period was 98,904[91]. - The largest shareholder, Kunshan Chuangye Investment Co., Ltd., holds 7.06% of the shares, totaling 72,671,714 shares[92]. - The second-largest shareholder, Zhongwei Small Enterprise Investment Group Co., Ltd., holds 4.99% of the shares, totaling 51,390,049 shares[92]. - The company did not distribute cash dividends or issue bonus shares for this period[6]. Cash Flow and Investments - The company reported a net cash outflow from investing activities of -¥6,586,586.37, a 105.57% decrease compared to a net inflow of ¥118,242,937.79 in the previous year[31]. - The cash outflow for the acquisition of fixed assets and other long-term assets was 90,000,000 CNY, indicating significant investment in growth[128]. - The company raised CNY 10,000,000.00 from borrowings during the current period, down from CNY 35,000,000.00 in the previous period[125]. Compliance and Governance - There were no significant litigation or arbitration matters affecting the company during the reporting period[58]. - The company has not engaged in any asset acquisitions or sales during the reporting period[62][63]. - The company did not undergo any significant changes in its shareholding structure or asset and liability structure during the reporting period[89]. - The half-year financial report has not been audited[81]. - The company does not face any risks of delisting due to legal violations during the reporting period[83]. Accounting Policies - The company prepares financial statements based on the going concern assumption and adheres to the accounting standards issued by the Ministry of Finance[145]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired[154]. - The company assesses the carrying value of financial assets for impairment at the balance sheet date, recognizing impairment losses for available-for-sale financial assets when fair value declines significantly[173]. - The company recognizes long-term equity investments using the cost method for subsidiaries and the equity method for joint ventures and associates[187].

江苏四环生物股份有限公司 2016 年第一季度报告正文 证券代码：000518 证券简称：四环生物 公告编号：临-2016-12 号 江苏四环生物股份有限公司 2016 年第一季度报告正文 1 江苏四环生物股份有限公司 2016 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐殷声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2016 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 58,968,046.44 | 46,987,464.09 | 25.50% | | ...

江苏四环生物股份有限公司 2015 年年度报告全文 江苏四环生物股份有限公司 2015 年年度报告 2016 年 04 月 1 江苏四环生物股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐殷声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 立信会计师事务所（特殊普通合伙）为公司出具了带强调事项段的无保留 意见的审计报告，本公司董事会、监事会对相关事项已有详细说明，请投资者 注意阅读。 江苏四环生物股份有限公司 2015 年年度报告全文 释义 | 释义项 | 指 | 释义内容 | | --- | --- | --- | | 公司、本公司 | 指 | 江苏四环生物股份有限公司 | | 北京四环 | 指 | 北京四环生物制药有限公司 | | 新疆爱迪 | 指 | 新疆爱迪新能源科技有限公司 | | 江苏四环制药 | 指 | 江苏 ...